Evolving research and stakeholder perspectives on pharmacogenomics.

THE PAST DECADE HAS BEEN A TIME OF IMPORTANT change in pharmacogenomics. There is an increasingly clear understanding of the relationship between genetic variation and drug response, lowcost testing technologies are becoming available, and pharmacogenomics is playing an increasing role in drug development. Key stakeholders in the US health care system are responding to these changes in various fashions. In this Commentary, we provide a brief overview of these developments and assess the implications for clinical practice.